Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol in Hepatic Impairment
NCT04480827Phase 1Completed
- Sponsor
- Galmed Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aramchol in Nonalcoholic steatohepatitis (NASH) (7 arms), sponsored by Galmed Pharmaceuticals. Primary endpoints: Area Under the Curve from Time 0 to Tau at Steady State at Day 12, Maximum Plasma Concentration at Steady State at Day 12 and 1 more. Started Feb 2020; status: completed.
02
Drugs
aramchol
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04480827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480827.